Cumulatively, based on these findings, we propose a model (Figure 5e) detailing the rationale for the dual targeting of AURKA and MAPK signaling in melanomas harboring the constitutively active BRAF(V600E) or NRAS (Q61R). Here, BRAF is linked to melanoma.